- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
Novo Nordisk A/S at UBS Global Healthcare Conference (Virtual) Transcript
Good morning, good afternoon, everybody. Welcome to this session. We have Kristoffer Berg with us from Novo Nordisk. We will go through 10, 15 minutes of prepared remarks, and we will then go into Q&A. If you have questions, you can submit them. We will see them on the screen, or I will see them on the screen. I can field them that way. And if there aren't any, then I will go ahead and ask questions myself.
Without further ado, Kristoffer, over to you.
/--
Thank you very much, Michael. And thank you, everybody, for the interest in Novo Nordisk and for dialing in today. It's, obviously, a different way to conduct a conference, but, I guess, this is the new world we all have to adapt to, and so are we at Novo Nordisk.
And as you probably saw, we released our Q1 financial results 2 weeks ago. And they were, obviously
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |